Mario Santinami

Mario Santinami

UNVERIFIED PROFILE

Are you Mario Santinami?   Register this Author

Register author
Mario Santinami

Mario Santinami

Publications by authors named "Mario Santinami"

Are you Mario Santinami?   Register this Author

80Publications

2446Reads

43Profile Views

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.

Melanoma Res 2017 08;27(4):309-314

aDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics bDepartment of Diagnostics and Public Health, University of Verona, Verona cMelanoma and Sarcoma Surgery Unit dUnit of Immunotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000360DOI Listing
August 2017

As easy as CC: a catchy, new mnemonic for the self-diagnosis of cutaneous melanoma.

G Ital Dermatol Venereol 2016 04;151(2):211-2

Day Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy -

View Article

Download full-text PDF

Source
April 2016

Electrochemotherapy: a good idea in recurrent basal cell carcinoma treatment.

Melanoma Manag 2015 Feb 25;2(1):27-31. Epub 2015 Feb 25.

Division of Oncologic Surgery, Melanoma & Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.14.28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094671PMC
February 2015

Armed antibodies for cancer treatment: a promising tool in a changing era.

Cancer Immunol Immunother 2015 Jan 15;64(1):113-21. Epub 2014 Oct 15.

Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, University Hospital of Siena, Strada delle Scotte, 53100, Siena, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-014-1621-0DOI Listing
January 2015

Prediction of survival in patients with thin melanoma: results from a multi-institution study.

J Clin Oncol 2014 Aug 7;32(23):2479-85. Epub 2014 Jul 7.

Andrea Maurichi, Rosalba Miceli, Tiziana Camerini, Luigi Mariani, Roberto Patuzzo, Roberta Ruggeri, Gianfranco Gallino, Elena Tolomio, Gabrina Tragni, Barbara Valeri, Andrea Anichini, Roberta Mortarini, Daniele Moglia, Mario Santinami, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori, Milan; Giovanni Pellacani, Sara Bassoli, Caterina Longo, University Hospital of Modena and Skin Cancer Unit IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia; Pietro Quaglino, University Hospital of Turin, Turin; Nicola Pimpinelli, Lorenzo Borgognoni, University Hospital of Florence and Istituto Tumori Toscano, S. Maria Annunziata Hospital, Florence, Italy; Daniele Bergamaschi, Catherine Harwood, Queen Mary University of London, London, United Kingdom; and Odysseas Zoras, University Hospital of Heraklion, Crete, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.2340DOI Listing
August 2014

Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.

J Invest Dermatol 2014 Jul 17;134(7):1893-1902. Epub 2014 Jan 17.

Unit of Immunotherapy of Human Tumor, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2014.29DOI Listing
July 2014

Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study.

J Clin Oncol 2014 Mar 10;32(9):935-41. Epub 2014 Feb 10.

Sandro Pasquali, Simone Mocellin, and Carlo Riccardo Rossi, University of Padova; Carlo Riccardo Rossi, Veneto Institute of Oncology, Padova; Nicola Mozzillo and Corrado Caracò, National Cancer Institute "Pascale," Naples; Andrea Maurichi and Ugo Marone, National Cancer Institute; Luigi Mascheroni, San Pio X Hospital, Milan; Pietro Quaglino, Roberto Patuzzo, and Mario Santinami, University of Turin, Turin; Lorenzo Borgognoni, Tuscan Tumor Institute, Florence; Nicola Solari and Simone Ribero, National Cancer Research Institute of Genova, Genova; Dario Piazzalunga, Riuniti Hospital, Bergamo; and Giuseppe Giudice, University of Bari, Bari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.7681DOI Listing
March 2014

Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience.

J Pediatr 2014 Feb 16;164(2):376-82.e1-2. Epub 2013 Nov 16.

Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpeds.2013.10.012DOI Listing
February 2014

Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.

Cancer Res 2014 Jan;74(1):130-40

Authors' Affiliations: Immunotherapy Unit; Department of Pathology; Functional Genomics Unit; Immunobiology of Human Tumors Unit; Department of Medical Statistics and University of Milan, Medical Statistics Biometry and Bioinformatics Unit; Department of Surgery, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Microscopy and Image Analysis, University of Milan Bicocca, Milan; Department of Immunohematology and Transfusion Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1672DOI Listing
January 2014

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

J Clin Oncol 2013 Oct 9;31(30):3831-7. Epub 2013 Sep 9.

Alexander M.M. Eggermont, Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, and Université Paris-Sud, Kremlin Bicêtre, Paris, France; Stefan Suciu, Larissa Polders, and Michel Praet, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Jeremy Marsden, University Hospital Birmingham, Birmingham; Philippa Corrie, Addenbrookes Hospital, Cambridge; Poulam M. Patel, University of Nottingham, Nottingham; Neville Davidson, Broomfield Hospital, Broomfield, United Kingdom; Mario Santinami, Istituto Nazionale dei Tumori, Milan; Paolo A. Ascierto, Istituto Nazionale Tumori Fondazione Pascale, Napoli; Lorenzo Borgognoni, Istituto Tumori Toscano, S. Maria Annunziata Hospital, Florence; Maria Grazia Bernengo, University Hospital Turin, Turin, Italy; Steinar Aamdal, Oslo University Hospital and Radium Hospital, Oslo, Norway; Wim H. Kruit, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; Lars Bastholt, Odense University Hospital, Odense, Denmark; and Alan Spatz, McGill University and Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.9303DOI Listing
October 2013

Biological insights into BRAF mutations in melanoma patient: Not mere therapeutic targets.

Oncoimmunology 2013 Aug 3;2(8):e25594. Epub 2013 Jul 3.

Laboratory of Clinical Research and Molecular Diagnostics; IRCCS - CROB Centro di Riferimento Oncologico della Basilicata; Rionero in Vulture (Pz), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.25594DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812198PMC
August 2013

A variant in FTO shows association with melanoma risk not due to BMI.

Nat Genet 2013 Apr 3;45(4):428-32, 432e1. Epub 2013 Mar 3.

Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, Leeds Cancer Research UK Centre, St. James's University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
https://genepi.qimr.edu.au/contents/p/staff/Iles_etal_Nature
Web Search
http://www.nature.com/doifinder/10.1038/ng.2571
Publisher Site
http://dx.doi.org/10.1038/ng.2571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640814PMC
April 2013

Small nodular melanoma: the beginning of a life-threatening lesion. A clinical study on 11 cases.

Tumori 2011 Jan-Feb;97(1):35-8

Day Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.

View Article

Download full-text PDF

Source
May 2011

Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior.

Ann Surg 2010 Dec;252(6):1052-7

Departments of Surgery and Biometry, Fonda-zione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0b013e3181efc23cDOI Listing
December 2010

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

Cancer Res 2010 Nov 21;70(21):8378-87. Epub 2010 Sep 21.

Human Tumors Immunobiology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-2028DOI Listing
November 2010

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

J Clin Oncol 2010 May 12;28(14):2460-6. Epub 2010 Apr 12.

Department of Surgery, Division Surgical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.24.6264DOI Listing
May 2010

Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone.

Ann Surg Oncol 2009 Nov 16;16(11):2985-93. Epub 2009 Jul 16.

Department of Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian 1, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-009-0615-1DOI Listing
November 2009

Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?

Cancer Immunol Immunother 2009 Jul 8;58(7):1159-67. Epub 2008 Nov 8.

Unit of Immunotherapy of Human Tumours, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-008-0610-6DOI Listing
July 2009

Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.

J Invest Dermatol 2009 Jul 22;129(7):1759-68. Epub 2009 Jan 22.

Melanoma Genetics, Department of Experimental Oncology, Immunotherapy of Human Tumors Unit, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2008.422DOI Listing
July 2009

Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage.

Clin Cancer Res 2009 Jun 9;15(12):4085-94. Epub 2009 Jun 9.

Department of Experimental Oncology, Human Tumors Immunobiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-3323DOI Listing
June 2009

Metamorphosis of melanoma. Trends in size and thickness of cutaneous melanoma over one decade at the Istituto Nazionale Tumori, Milan.

Tumori 2008 Jan-Feb;94(1):11-3

Day Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
June 2008

Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.

Int J Cancer 2007 Jun;120(11):2439-44

Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.22598DOI Listing
June 2007

Melanoma immunology: past, present and future.

Curr Opin Oncol 2007 Mar;19(2):121-7

Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori Foundation, Milan, Italy.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00001622-200703000-000
Publisher Site
http://dx.doi.org/10.1097/CCO.0b013e32801497d7DOI Listing
March 2007

Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution.

Ann Surg Oncol 2007 Feb 23;14(2):553-9. Epub 2006 Nov 23.

Department of Surgery, Istituto Nazionale per lo studio e la cura dei Tumori, via Venezian, 1, 20133, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-006-9251-1DOI Listing
February 2007

Vaccination: role in metastatic melanoma.

Expert Rev Anticancer Ther 2006 Aug;6(8):1305-18

Istituto Nazionale per lo Studio e la Cura dei Tumori, Unit of Immunotherapy of Human Tumors, Via Venezian 1, 20133 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.6.8.1305DOI Listing
August 2006

Automated segmentation of pigmented skin lesions in multispectral imaging.

Phys Med Biol 2005 Nov 1;50(22):N345-57. Epub 2005 Nov 1.

Medical Physics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/0031-9155/50/22/N01DOI Listing
November 2005

Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles.

Cancer Res 2005 Apr;65(8):3428-36

Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-3239DOI Listing
April 2005

Narrower surgical margins might be sufficient in invasive horizontal growth phase melanoma.

Tumori 2004 Sep-Oct;90(5):464-6

Melanoma and Sarcoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
February 2005

Pigmented spindle-cell nevus: a melanoma simulator.

Dermatol Online J 2004 Oct 15;10(2). Epub 2004 Oct 15.

Melanoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
October 2004

Micro-melanoma detection. A clinical study on 22 cases of melanoma with a diameter equal to or less than 3 mm.

Tumori 2004 Jan-Feb;90(1):128-31

Melanoma and Sarcoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
June 2004

Immunotherapy of melanoma.

Semin Cancer Biol 2003 Dec;13(6):391-400

Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian, 1-20133 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2003.09.001DOI Listing
December 2003

E-cadherin expression on fine needle aspiration biopsies of breast invasive ductal carcinomas and its relationship to clinicopathologic factors.

Acta Cytol 2003 May-Jun;47(3):363-7

Department of Cytopathology, Medical School, University of Crete, P.O. Box 1393, Heraklion 71110, Crete, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000326534DOI Listing
June 2003

Clinical and dermatoscopic diagnosis of small pigmented skin lesions.

Eur J Dermatol 2002 Nov-Dec;12(6):573-6

Melanoma Unit, Istituto Nazionale per lo studio e la cura dei Tumori, Via Venezian 1, 20133, Milan, Italy.

View Article

Download full-text PDF

Source
March 2003